Skip to main navigation
Skip to search
Skip to main content
The Capital Region of Denmark's Research Portal Home
Dansk
English
Search content at The Capital Region of Denmark's Research Portal
Home
Hospitals/Departments
Researchers
Research output
Activities
Prizes
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer
Kristoffer B. Kristensen
*
, Ida Marie Nedergaard Thomsen
,
Tobias Berg
, Annette R. Kodahl
, Anders Bonde Jensen
*
Corresponding author for this work
27
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Dose Adjustment
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Dose Reduction
100%
Metastatic Breast Cancer
100%
Estrogen Receptor-positive
100%
Endocrine Therapy
100%
Ribociclib
100%
Cyclin-dependent Kinase 4 (CDK4)
40%
Retrospective Cohort Study
20%
Adverse Events
20%
Clinical Trials
20%
Tolerability
20%
Study Support
20%
Progression-free Survival
20%
Neutropenia
20%
Aromatase Inhibitors
20%
Fulvestrant
20%
Lymph Node Involvement
20%
Oncology Department
20%
Electronic Health Records
20%
Real-world Clinical Practice
20%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor
100%
Endocrine Therapy
100%
Estrogen Receptor
100%
Metastatic Breast Cancer
100%
Ribociclib
100%
Cohort Study
20%
Adverse Event
20%
Clinical Trial
20%
Tolerability
20%
Progression Free Survival
20%
Neutropenia
20%
Aromatase Inhibitor
20%
Fulvestrant
20%